Neal Edward Ready, MD, PhD, Duke Medical Center

Articles

Audience Q&A: Emerging Therapeutic Targets in Advanced NSCLC

August 12th 2022

Closing out their discussion on the treatment paradigm of advanced NSCLC, key opinion leaders review emerging targets and ongoing clinical trials.

CheckMate 9LA: Dual IO Therapy With Chemotherapy in Advanced NSCLC

August 5th 2022

Shared insight on the CheckMate 9LA trial, which combined dual IO therapy with chemotherapy in the setting of advanced non–small cell lung cancer.

Dual IO Therapy in Advanced NSCLC: Long-Term Followup From CheckMate 227

August 5th 2022

Expert perspectives on the CheckMate 227 clinical trial, which combined ipilimumab and nivolumab IO therapy in patients with advanced NSCLC.

Discontinuing Chemoimmunotherapy in Advanced NSCLC

July 29th 2022

A brief discussion on when it is appropriate to discontinue chemoimmunotherapy in patients with advanced non–small cell lung cancer.

Chemoimmunotherapy Combinations in Advanced NSCLC

July 29th 2022

Shifting their focus to chemoimmunotherapy combinations in advanced NSCLC, experts review clinical trial data from KEYNOTE-189, IMpower150, and EMPOWER-Lung 3.

Advanced NSCLC: IO Monotherapy Selection Based on PD-L1 Expression

July 22nd 2022

Shared insight on the optimal selection and use of single-agent immunotherapy guided by the testing and expression of PD-L1.

Toxicity Profiles of Immunotherapy Agents in Advanced NSCLC

July 22nd 2022

A brief review of AEs seen with immunotherapy in advanced non–small cell lung cancer followed by advice on how to nuance safety data in this setting.

Dr. Ready on the Practice Implications of Nivolumab/Ipilimumab in NSCLC

July 21st 2022

Neal Edward Ready, MD, PhD, discusses the practice implications of nivolumab plus ipilimumab in patients with metastatic non–small cell lung cancer.

Advanced NSCLC: The Advent of Frontline IO Monotherapy

July 15th 2022

Focusing on single-agent immunotherapy in advanced NSCLC, experts review key data from the KEYNOTE-024, IMpower110, and EMPOWER-Lung 1 clinical trials.

Paradigm for Immunotherapy in Advanced Non-Small Cell Lung Cancer

July 15th 2022

Expert oncologists review the current state of molecular testing and PD-L1 expression in the setting of advanced non–small cell lung cancer management.

Immunotherapy for NSCLC: Clinical Pearls

August 25th 2021

Final takeaways from ASCO 2021 and the use of immunotherapy to treat various types of patients with non–small cell lung cancer.

Blood-Based Biomarkers in NSCLC

August 25th 2021

The potential clinical utility of blood-based biomarkers in non–small cell lung cancer based on recent data presented at ASCO 2021.

Perioperative Approaches to NSCLC

August 25th 2021

Drs Chaitali Nangia and Sandip P. Patel debate between best treatment approaches for patients with non–small cell lung cancer in the perioperative setting.

Biomarkers for Immunotherapy in Resectable NSCLC

August 18th 2021

Dr Roy S. Herbst comments on the utilization of biomarkers and information needed to help aid in treatment decisions about perioperative therapy for patients with resectable non–small cell lung cancer.

Atezolizumab After Adjuvant Chemotherapy in Resectable NSCLC

August 18th 2021

Dr Martin Dietrich comments on the IMpower010 trial of atezolizumab versus best supportive care after adjuvant chemotherapy in patients with resected non–small cell lung cancer.

Clinical Endpoints and Neoadjuvant Therapy for Resectable NSCLC

August 11th 2021

The impact of endpoints used in clinical trials of neoadjuvant therapy for resectable non–small cell lung cancer as they relate to newer drug approvals and real-world practice.

Neoadjuvant Immunotherapy for Resectable NSCLC

August 11th 2021

Martin Dietrich, MD, PhD, describes his interpretations of the KEYNOTE-799 study of pembrolizumab plus chemoradiation therapy for unresectable stage III non–small cell lung cancer.

CRT and I-O for Unresectable Stage III NSCLC

August 4th 2021

Martin Dietrich, MD, PhD, describes his interpretations of the KEYNOTE-799 study of pembrolizumab plus chemoradiation therapy for unresectable stage III non–small cell lung cancer.

Appropriateness for Durvalumab in Unresectable Stage III NSCLC

August 4th 2021

Variables that influence patient selection for durvalumab consolidation after CRT as part of treatment for unresectable stage III non–small cell lung cancer.

Risks of Pneumonitis in Unresectable Stage III NSCLC

July 28th 2021

How to differentiate whether a patient with unresectable stage III non–small cell lung cancer develops pneumonitis from chemoradiation or durvalumab, and insight regarding techniques to help manage treatment toxicities.